Cancelled

Day One
Wednesday 12th December 2018

Day Two
Thursday 13th December 2018

08.00
Chair’s Opening Remarks

  • Sheena Aurora Medical Fellow Global Launch Leader Pain, Eli Lilly

08.40
Keynote: Migraine; From Hysteria to Neurobiological Entity

  • Sheena Aurora Medical Fellow Global Launch Leader Pain, Eli Lilly

Synopsis

  • Understand pathophysiology data from imaging studies
  • Summarize new guidelines on developing Acute Treatment for Migraine
  • Assess treatment gaps in Preventive treatment of Migraine and the unmet
    patient need

09.10
Keynote: Exploring Opportunities for Funding for Translational Research in Migraine

  • Michael Oshinsky Program Director Pain & Migraine , National Institute of Health

Synopsis

  • Investigating the funding decisions and grants at the NIH
  • How to best gain funding opportunities from the NIH
  • Delving into the HEAL initiative, helping to end addiction long term

09.40
Speed Networking

Synopsis

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the Migraine field and establish meaningful business relationships.

10.10
Morning Refreshments

Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose

11.00
Sharing Key Clinical Data from a CGRP Study, How is the Future Looking?

  • Daniel Mikol Executive Medical Director, Global Neuroscience Development, Amgen

Synopsis

  • Details to Follow

11.30
Investigating CGRP Monoclonal Antibodies Mechanism of Action & What it Teaches Us About Migraine

Synopsis

  • Understanding migraine pathophysiology and diagnosis before CGRP-mAbs
  • CGRP-mAbs sites of action
  • Understanding migraine pathophysiology and diagnosis after CGRP-mAbs

12.00
Analysing Clinical Trial Data from Anti CGRP Monoclonal Antibodies Studies

  • Roger Cady Vice President, Neurology, Alder Biopharmaceuticals

Synopsis

  • Validation of CGRP in the pathophysiology of migraine
  • Analyzing results from Eptinezumab trials and comparing these in the grand scheme of CGRP trials
  • Unique advances to prophylactic therapeutics that CGRP antibodies represents over existing therapies

12.30
Lunch and Networking

Expanding on Novel Devices & Technologies, Evaluating the Challenges & the Future of Device & Device/Drug Combination Therapies in Migraine Drug Development

13.30
A Device is Not a Drug – The Intersection of Clinical Development, Regulatory Approval & Commercial Success

  • Eric Liebler Senior Vice President, Neurology, Electrocore

Synopsis

  • Highlight the important differences between drugs and devices
  • Understand how study design can influence review and acceptance
  • How to be positioned for long term sucess

14.00
Keeping Up With the Pace of Innovation in Migraine Drug Development

Synopsis

  • Details to Follow

14.30
Exploring ADAM, a Novel Drug Delivery Platform for Treatment of Acute Migraine

Synopsis

  • A novel intracutaneous microprojection system for parathyroid hormone, glucagon, and zolmitriptan has been developed by Zosano.
  • Intracutaneously administered zolmitriptan was highly effective for the treatment of migraine, with statistical significance compared to placebo achieved for the two co-primary endpoints of pain freedom at 2 hours, and most bothersome symptom absence at 2 hours
  •  In combination with our ongoing long term safety study we believe this trial will form the basis for approval. The results in the three distinct patient populations show the usefulness of the intracutaneous microprojection system for delivering drugs rapidly and yielding pharmacologic effects quickly.

15.00
Afternoon Refreshments & Networking

16.00
Think Tank Roundtable Sessions

Synopsis

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

16.30
Moderator Feedback & Audience Debate

Synopsis

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion to share ideas and best practice.

17.00
Chair’s Closing Remarks

  • Sheena Aurora Medical Fellow Global Launch Leader Pain, Eli Lilly

17.10
Poster Session

Synopsis

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.